Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT07226726
PHASE1
Patients With Congenital Myasthenic Syndrome Will be Treated With Umbilical or Placental Derived Mesenchymal Stem Cell Exosome Solution
Sponsor: The Foundation for Orthopaedics and Regenerative Medicine
View on ClinicalTrials.gov
Summary
Patients with Congenital Myasthenic Syndrome will be treated with Umbilical or Placental Derived Mesenchymal Stem Cell Exosome solution.
Official title: Mesenchymal Stem Cell Exosome Treatment of Congenital Myasthenic Syndrome
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2025-01-01
Completion Date
2028-12-31
Last Updated
2026-10-16
Healthy Volunteers
No
Conditions
Interventions
BIOLOGICAL
AlloEx exosomes
This is an intranasal treatment of exosomes derived from mesenchymal stem cells.
Locations (2)
Prodromos Stem Cell Institute
Naples, Florida, United States
Prodromos Stem Cell Institute
Athens, Greece